Project aimed at making neuroimaging data sets of brain freely available to scientific community. By compiling and freely distributing neuroimaging data sets, future discoveries in basic and clinical neuroscience are facilitated.

Context:

The Open Access Series of Imaging Studies (OASIS) is a project aimed at making MRI data sets of the brain freely available to the scientific community. By compiling and freely distributing MRI data sets, we hope to facilitate future discoveries in basic and clinical neuroscience. OASIS is made available by the Washington University Alzheimer’s Disease Research Center, Dr. Randy Buckner at the Howard Hughes Medical Institute (HHMI)( at Harvard University, the Neuroinformatics Research Group (NRG) at Washington University School of Medicine, and the Biomedical Informatics Research Network (BIRN).

Content:

• Cross-sectional MRI Data in Young, Middle Aged, Nondemented and Demented Older Adults: This set consists of a cross-sectional collection of 416 subjects aged 18 to 96. For each subject, 3 or 4 individual T1-weighted MRI scans obtained in single scan sessions are included. The subjects are all right-handed and include both men and women. 100 of the included subjects over the age of 60 have been clinically diagnosed with very mild to moderate Alzheimer’s disease (AD). Additionally, a reliability data set is included containing 20 nondemented subjects imaged on a subsequent visit within 90 days of their initial session.
• Longitudinal MRI Data in Nondemented and Demented Older Adults: This set consists of a longitudinal collection of 150 subjects aged 60 to 96. Each subject was scanned on two or more visits, separated by at least one year for a total of 373 imaging sessions. For each subject, 3 or 4 individual T1-weighted MRI scans obtained in single scan sessions are included. The subjects are all right-handed and include both men and women. 72 of the subjects were characterized as nondemented throughout the study. 64 of the included subjects were characterized as demented at the time of their initial visits and remained so for subsequent scans, including 51 individuals with mild to moderate Alzheimer’s disease. Another 14 subjects were characterized as nondemented at the time of their initial visit and were subsequently characterized as demented at a later visit.

Acknowledgements:

When publishing findings that benefit from OASIS data, please include the following grant numbers in the acknowledgements section and in the associated Pubmed Central submission: P50 AG05681, P01 AG03991, R01 AG021910, P20 MH071616, U24 RR0213

Inspiration:

Can you predict dementia? Alzheimer’s?

These brains have been classified by IVAM and denoised using an Ising model.

Introduction: It has been shown that Alzheimer’s disease (AD) is accompanied by marked structural brain changes that can be detected several years before clinical diagnosis via structural magnetic resonance (MR) imaging. In this study, we developed a structural MR-based biomarker for in vivo detection of AD using a supervised machine learning approach. Based on an individual’s pattern of brain atrophy a continuous AD score is assigned which measures the similarity with brain atrophy patterns seen in clinical cases of AD.Methods: The underlying statistical model was trained with MR scans of patients and healthy controls from the Alzheimer’s Disease Neuroimaging Initiative (ADNI-1 screening). Validation was performed within ADNI-1 and in an independent patient sample from the Open Access Series of Imaging Studies (OASIS-1). In addition, our analyses included data from a large general population sample of the Study of Health in Pomerania (SHIP-Trend).Results: Based on the proposed AD score we were able to differentiate patients from healthy controls in ADNI-1 and OASIS-1 with an accuracy of 89% (AUC = 95%) and 87% (AUC = 93%), respectively. Moreover, we found the AD score to be significantly associated with cognitive functioning as assessed by the Mini-Mental State Examination in the OASIS-1 sample after correcting for diagnosis, age, sex, age·sex, and total intracranial volume (Cohen’s f2 = 0.13). Additional analyses showed that the prediction accuracy of AD status based on both the AD score and the MMSE score is significantly higher than when using just one of them. In SHIP-Trend we found the AD score to be weakly but significantly associated with a test of verbal memory consisting of an immediate and a delayed word list recall (again after correcting for age, sex, age·sex, and total intracranial volume, Cohen’s f2 = 0.009). This association was mainly driven by the immediate recall performance.Discussion: In summary, our proposed biomarker well differentiated between patients and healthy controls in an independent test sample. It was associated with measures of cognitive functioning both in a patient sample and a general population sample. Our approach might be useful for defining robust MR-based biomarkers for other neurodegenerative diseases, too.

Information for OASIS and IBSR datasets.

Note: P = parametric; NP = nonparametric; ADNI = Alzheimer’s Disease Neuroimaging Initiative; OASIS = Open Access Series of Imaging Studies. Rounding errors mean that not all rows in this table sum to exactly 1.Proportions of differing classifications by lobe.

Segmentation result comparisons between the proposed, the conventional U-net, and SegNet based methods for OASIS and IBSR datasets (DSC: Dice Similarity Coefficient, JI: Jaccard Index, MSE: Mean Square error, GM: Grey Matter, WM: White Mater, CSF: Cerebrospinal Fluid, HD: Hausdorff distance).

BackgroundAccording to the World Health Organization (WHO), dementia is the seventh leading reason of death among all illnesses and one of the leading causes of disability among the world’s elderly people. Day by day the number of Alzheimer’s patients is rising. Considering the increasing rate and the dangers, Alzheimer’s disease should be diagnosed carefully. Machine learning is a potential technique for Alzheimer’s diagnosis but general users do not trust machine learning models due to the black-box nature. Even, some of those models do not provide the best performance because of using only neuroimaging data.ObjectiveTo solve these issues, this paper proposes a novel explainable Alzheimer’s disease prediction model using a multimodal dataset. This approach performs a data-level fusion using clinical data, MRI segmentation data, and psychological data. However, currently, there is very little understanding of multimodal five-class classification of Alzheimer’s disease.MethodFor predicting five class classifications, 9 most popular Machine Learning models are used. These models are Random Forest (RF), Logistic Regression (LR), Decision Tree (DT), Multi-Layer Perceptron (MLP), K-Nearest Neighbor (KNN), Gradient Boosting (GB), Adaptive Boosting (AdaB), Support Vector Machine (SVM), and Naive Bayes (NB). Among these models RF has scored the highest value. Besides for explainability, SHapley Additive exPlanation (SHAP) is used in this research work.Results and conclusionsThe performance evaluation demonstrates that the RF classifier has a 10-fold cross-validation accuracy of 98.81% for predicting Alzheimer’s disease, cognitively normal, non-Alzheimer’s dementia, uncertain dementia, and others. In addition, the study utilized Explainable Artificial Intelligence based on the SHAP model and analyzed the causes of prediction. To the best of our knowledge, we are the first to present this multimodal (Clinical, Psychological, and MRI segmentation data) five-class classification of Alzheimer’s disease using Open Access Series of Imaging Studies (OASIS-3) dataset. Besides, a novel Alzheimer’s patient management architecture is also proposed in this work.

BackgroundAccording to the World Health Organization (WHO), dementia is the seventh leading reason of death among all illnesses and one of the leading causes of disability among the world’s elderly people. Day by day the number of Alzheimer’s patients is rising. Considering the increasing rate and the dangers, Alzheimer’s disease should be diagnosed carefully. Machine learning is a potential technique for Alzheimer’s diagnosis but general users do not trust machine learning models due to the black-box nature. Even, some of those models do not provide the best performance because of using only neuroimaging data.ObjectiveTo solve these issues, this paper proposes a novel explainable Alzheimer’s disease prediction model using a multimodal dataset. This approach performs a data-level fusion using clinical data, MRI segmentation data, and psychological data. However, currently, there is very little understanding of multimodal five-class classification of Alzheimer’s disease.MethodFor predicting five class classifications, 9 most popular Machine Learning models are used. These models are Random Forest (RF), Logistic Regression (LR), Decision Tree (DT), Multi-Layer Perceptron (MLP), K-Nearest Neighbor (KNN), Gradient Boosting (GB), Adaptive Boosting (AdaB), Support Vector Machine (SVM), and Naive Bayes (NB). Among these models RF has scored the highest value. Besides for explainability, SHapley Additive exPlanation (SHAP) is used in this research work.Results and conclusionsThe performance evaluation demonstrates that the RF classifier has a 10-fold cross-validation accuracy of 98.81% for predicting Alzheimer’s disease, cognitively normal, non-Alzheimer’s dementia, uncertain dementia, and others. In addition, the study utilized Explainable Artificial Intelligence based on the SHAP model and analyzed the causes of prediction. To the best of our knowledge, we are the first to present this multimodal (Clinical, Psychological, and MRI segmentation data) five-class classification of Alzheimer’s disease using Open Access Series of Imaging Studies (OASIS-3) dataset. Besides, a novel Alzheimer’s patient management architecture is also proposed in this work.

BackgroundAccording to the World Health Organization (WHO), dementia is the seventh leading reason of death among all illnesses and one of the leading causes of disability among the world’s elderly people. Day by day the number of Alzheimer’s patients is rising. Considering the increasing rate and the dangers, Alzheimer’s disease should be diagnosed carefully. Machine learning is a potential technique for Alzheimer’s diagnosis but general users do not trust machine learning models due to the black-box nature. Even, some of those models do not provide the best performance because of using only neuroimaging data.ObjectiveTo solve these issues, this paper proposes a novel explainable Alzheimer’s disease prediction model using a multimodal dataset. This approach performs a data-level fusion using clinical data, MRI segmentation data, and psychological data. However, currently, there is very little understanding of multimodal five-class classification of Alzheimer’s disease.MethodFor predicting five class classifications, 9 most popular Machine Learning models are used. These models are Random Forest (RF), Logistic Regression (LR), Decision Tree (DT), Multi-Layer Perceptron (MLP), K-Nearest Neighbor (KNN), Gradient Boosting (GB), Adaptive Boosting (AdaB), Support Vector Machine (SVM), and Naive Bayes (NB). Among these models RF has scored the highest value. Besides for explainability, SHapley Additive exPlanation (SHAP) is used in this research work.Results and conclusionsThe performance evaluation demonstrates that the RF classifier has a 10-fold cross-validation accuracy of 98.81% for predicting Alzheimer’s disease, cognitively normal, non-Alzheimer’s dementia, uncertain dementia, and others. In addition, the study utilized Explainable Artificial Intelligence based on the SHAP model and analyzed the causes of prediction. To the best of our knowledge, we are the first to present this multimodal (Clinical, Psychological, and MRI segmentation data) five-class classification of Alzheimer’s disease using Open Access Series of Imaging Studies (OASIS-3) dataset. Besides, a novel Alzheimer’s patient management architecture is also proposed in this work.